A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
The purpose of this study is to determine if MEDI4736 will be adequately tolerated in combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).
Checked against the public recordLast updated Oct 31, 2019 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- MedImmune LLC
- Interventions being studied
- Drug: MEDI4736; Drug: Tremelimumab; Drug: tremelimumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: 1. Age ≥ 18 years 2. Advanced non-small cell lung cancer 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 4. Adequate organ and marrow function Exclusion Criteria: 1. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment 2. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drugs 3. Active or prior documented autoimmune disease within the last 2 years.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Research SiteBirmingham, Alabama
- Research SiteTucson, Arizona
- Research SiteLos Angeles, California
- Research SiteLos Angeles, California
- Research SiteSan Francisco, California
- Research SiteAurora, Colorado
- Research SiteNew Haven, Connecticut
- Research SiteNewark, Delaware
- Research SiteTampa, Florida
- Research SiteIndianapolis, Indiana
- Research SiteBaltimore, Maryland
- Research SiteBoston, Massachusetts
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 31, 2019. Always confirm current availability with the study team.